# FIRST-308 (NCT05948475)

> Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05948475
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: TransThera Sciences (Nanjing), Inc.
- Conditions: Cholangiocarcinoma
- Interventions: Tinengotinib 8 mg; Tinengotinib 10 mg; Physician's Choice
- Enrollment: 200
- Primary outcome: Part A: Incidence, duration, and severity of adverse events (AEs)
- Primary outcome: Part B: PFS by BICR

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=first-308-nct05948475